O le Ruxolitinib o se mole laʻititi Janus kinase inhibitor lea e faʻaaogaina i le togafitiga o le myelofibrosis maualuga poʻo le maualuga ma faʻamaʻi faʻamaʻi o le polycythemia vera ma faʻamaʻi pipisi-vs-host.O le Ruxolitinib e fesoʻotaʻi ma faʻalavelave faʻafuaseʻi ma e masani ona faʻaitiitia le maualuga o le aminotransferase i le taimi o togafitiga ma e seasea lava faʻamaʻi faʻamaʻi, faʻamaʻi faʻamaʻi faʻamaʻi manuʻa ate faʻapea foʻi ma mataupu o le toe faʻafouina o le hepatitis B i tagata maʻi.

O le Ruxolitinib o se fa'agata Janus-associated kinase (JAK) e mafai ona tu'u tautala ma gaioiga antineoplastic ma le immunomodulating.Ruxolitinib faʻapitoa e fusifusia ma faʻalavelaveina polotinityrosinekinases JAK 1 ma le 2, lea e mafai ona oʻo atu ai i le faʻaitiitia o le mumū ma le faʻalavelaveina o le faʻalauteleina o le telefoni.O le JAK-STAT (signal transducer and activator of transcription) o loʻo i ai se sao taua i le faʻailogaina o le tele o cytokines ma mea faʻatupulaia ma e aʻafia i le faʻalauteleina o le telefoni feaveaʻi, tuputupu aʻe, hematopoiesis, ma le tali atu;JAK kinases e mafai ona faʻatonutonuina i faʻamaʻi faʻamaʻi, faʻafitauli o le myeloproliferative, ma faʻamaʻi eseese.

Ruxolitinib o sepyrazolesuia i le tulaga 1 e se vaega 2-cyano-1-cyclopentylethyl ma i le tulaga 3 e se pyrrolo [2,3-d] pyrimidin-4-yl vaega.Fa'aaogaina e fai ma masima phosphate mo le togafitia o tagata mama'i e maua i le myelofibrosis tulagalua pe maualuga, e aofia ai le myelofibrosis muamua, post-polycythemia vera myelofibrosis ma le post-essential thrombocythemia myelofibrosis.E iai sona sao e fai ma sui o le antineoplastic ma se EC 2.7.10.2 (polotini e le fa'apitoa-tyrosinekinase) inhibitor.O le nitrile, apyrrolopyrimidinema se sui o pyrazoles.